|
|
|
|
|||||
|
|
|
The visualization specialist posted its third quarter results.
It beat on the bottom line and missed slightly on revenue, but investors were cheered by other developments.
Medical imaging specialist Nano-X Imaging (NASDAQ: NNOX) was a big hit on the stock market Friday, following the company's publication of its latest set of quarterly earnings. Investors flocked to the stock to push it more than 26% higher that trading session.
Just after market close on Thursday, Nano-X unveiled its third-quarter figures. The company's revenue was $3.45 million, representing a sturdy 13% year-over-year increase. On the other hand, its net loss not according to generally accepted accounting principles (GAAP) deepened, coming in at $9.9 million ($0.15) against the year-ago deficit of $8.7 million.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
Despite the red bottom-line number, it was better than analysts expected. On average, pundits tracking the stock were modeling a loss of $0.19 for that line item. Nano-X narrowly missed on the top line, as the consensus estimate from those prognosticators was $3.5 million.
Yet investors are generally more concerned with what's ahead for a company, rather than what it's done in the recent past. Although the company didn't proffer any financial guidance for the entirety of the current year, it did post a revenue estimate for next year of $35 million. If achieved, this would be more than three times the total for 2024.
Nano-X highlighted several other recent developments that should aid in achieving that goal. One is the recently announced acquisition of healthcare tech company Vaso Healthcare IT, which, like its parent-to-be, is a cutting-edge business in its niche. The company also announced a push into the European market with the signing of two distribution deals on that continent.
While Friday's investor reaction was perhaps a touch too enthusiastic, I'd say Nano-X seems to be going in the right direction. And if its European foray is successful, it'll be selling into more than one market with an aging demographic that will need more healthcare assets before long.
Before you buy stock in Nano-X Imaging, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nano-X Imaging wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $569,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,107,298!*
Now, it’s worth noting Stock Advisor’s total average return is 982% — a market-crushing outperformance compared to 185% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of November 17, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
| 2 hours | |
| Nov-20 | |
| Nov-20 | |
| Nov-19 | |
| Nov-19 | |
| Nov-18 | |
| Nov-14 | |
| Nov-13 | |
| Nov-07 | |
| Nov-06 | |
| Oct-21 | |
| Sep-18 | |
| Sep-18 | |
| Sep-16 | |
| Aug-13 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite